HilleVax was a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, most notably HIL-214, a virus-like-particle based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis caused by norovirus infection. - View it on GitHub